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Abstract: Intensive glycemic control using insulin therapy may be appropriate for many healthy 
older adults to reduce premature mortality and morbidity, improve quality of life, and reduce 
health care costs. However, frail elderly people are more prone to develop complications from 
hypoglycemia, such as confusion and dementia. Overall, older persons with type 2 diabetes 
mellitus are at greater risk of death from cardiovascular disease (CVD) than from intermit-
tent hyperglycemia; therefore, diabetes management should always include CVD prevention 
and treatment in this patient population. Pharmacists can provide a comprehensive medica-
tion review with subsequent recommendations to individualize therapy based on medical and 
cognitive status. As part of the patient’s health care team, pharmacists can provide continuity 
of care and communication with other members of the patient’s health care team. In addition, 
pharmacists can act as educators and patient advocates and establish patient-specific goals to 
increase medication effectiveness, adherence to a medication regimen, and minimize the likeli-
hood of adverse events.
Keywords: glycemic control, hyperglycemia, continuity of care, hypertension and   cardiovascular 
disease, elderly, type 2 diabetes, pharmacist
Introduction
More than 20% of elderly Americans (65 years or older) have type 2 diabetes mellitus 
(T2DM).1 T2DM is associated with increased morbidity and mortality in the elderly,2 
and half of elderly patients receiving diabetes treatment do not achieve adequate 
  glycemic control.3 Although glycemic control is important, elderly patients with 
diabetes are more likely to benefit from the additional treatment for hypertension and 
cardiovascular disease (CVD) than with only tight glycemic control.1 Compared with 
a younger cohort, older Americans with diabetes are more likely to have geriatric 
syndrome, which is a cluster of conditions that include injurious falls, cognitive impair-
ment, and depression.4 These conditions can complicate the management of diabetes 
and increase the likelihood of hypoglycemia, confusion, and dementia. As part of the 
patient’s health care team, pharmacists can act as educators and patient advocates and 
establish patient-specific goals to increase medication effectiveness and adherence to 
their medication regimen, and minimize adverse events. For example, pharmacists 
who participated in the Diabetes Ten City Challenge (DTCC) provided coaching, used 
evidence-based diabetes care guidelines, and implemented patient self-management 
strategies, which resulted in reductions in glycosylated hemoglobin, low-density 
lipoprotein cholesterol, and systolic blood pressure in 573 patients with diabetes after 
1 year of follow-up.5 Pharmacists referred patients to physicians for further assessment, Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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contacted other providers (such as a dietitian) for intensive 
nutrition education, or communicated with diabetes education 
centers for additional education support.
Special considerations for elderly 
patients with diabetes
Elderly persons are more likely to develop and be more 
susceptible to diabetes-related complications.1 In particular, 
this population should be evaluated for complications that 
develop over short periods of time and/or for those that 
would significantly impair functional status, such as vision 
and lower-extremity complications (ie, peripheral neu-
ropathy and subsequent diabetic foot infections). Diabetes 
treatment-related complications may be more problematic 
in elderly persons than in the nonelderly; for example, 
hypoglycemia may aggravate dementia6 and can increase 
the risk of falls. Elderly persons may be at greater risk than 
younger patients for comorbid conditions such as depression, 
which can lead to treatment apathy and reduced medication 
effectiveness.
Adherence to a prescribed medication regimen should 
not be assumed. About 30% of Medicare patients with 
medication coverage are nonadherent to their medication 
regimens for financial reasons.7 Patients who repeatedly miss 
medical appointments may be at increased risk for nonad-
herence and will likely require diligent follow-up measures 
to resolve underlying issues. A comprehensive medication 
review by the pharmacist, which includes medication adher-
ence and individual strategies to decrease nonadherence, 
can help identify other medication-related issues. Elderly 
patients may not be able to read their medication instruc-
tions or understand how to take the medications; these issues 
can be addressed with additional education and repeated 
  interventions. Taking multiple drugs several times a day can 
lead to medication errors, adverse events, reduced medica-
tion efficacy, increased costs, and poor regimen adherence.8 
Polypharmacy is common, as elderly persons tend to keep 
medications that were prescribed years ago, and may keep 
medications that were switched to another drug within the 
same drug class after a hospitalization. Medication recon-
ciliation should include discontinuing medications that are 
a therapeutic duplication, or that contain the same active 
ingredient but were prescribed as a different formulation 
or as part of a combination drug.
Diabetes self-management weaknesses and the patient’s 
history of hypoglycemic events should be addressed by a 
pharmacist and other health care providers so action can 
be taken to prevent future events. Assessing for cognitive 
decline or depression is necessary to differentiate these 
  disorders from symptoms related to hypoglycemia. If a 
patient is diagnosed with and treated for depression, the 
patient should be reevaluated to assess treatment efficacy 
and symptom improvement. Working with the patient and 
prescribers to simplify treatment regimens may increase 
medication regimen adherence, minimize adverse effects, 
and increase medication effectiveness.
Diabetes treatment guidelines  
for the elderly
Treatment goals should be developed and achieved in line 
with the elderly patient’s medical, functional, social, and 
financial status.4 Aggressive treatment is appropriate for 
most healthy older adults to reduce premature mortality 
and morbidity, improve quality of life, and reduce health 
care costs.1 These patients may benefit from regimens 
that include insulin to allow dosage adjustment with food 
intake and level of exercise. However, due to a patient’s 
advancing age, treatment decisions become more com-
plex, and their capacity to cope with adverse effects and 
complicated treatment regimens declines. To minimize the 
risk of hypoglycemia and associated complications such as 
falls or confusion, less aggressive fasting glucose targets 
may be necessary for frail elderly patients9 (those with an 
unintentional weight loss of 10 pounds in the past year, 
chronic exhaustion, and low grip strength, walking speed, 
and physical activity).10 For these frail elderly patients, 
treatment selection should include therapies with a low 
risk of hypoglycemia, such as metformin or an incretin 
mimetic; therapies with a high risk of hypoglycemia, 
such as long-acting sulfonylureas (ie, chlorpropamide or 
glyburide), should be avoided.
The long-term benefits of tight control of fasting blood 
glucose will likely not be observed in patients with advanced 
age. Cardiovascular disease is a leading cause of death in 
this population,11 and a greater reduction in morbidity and 
mortality is expected by controlling CVD risk factors.12 
Elevated postprandial glucose (PPG) levels may increase the 
risk of CVD.13 Data on PPG control in the elderly are limited; 
however, selecting drug therapy that targets PPG should be 
considered to further reduce CVD risk. Elderly patients and 
caregivers should be educated about controlling CVD risk 
factors by discussing the importance of smoking cessation 
and blood pressure control. Pharmacists can provide continu-
ity of care by communicating changes in over-the-counter Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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medications or herbal therapies to the patient’s prescriber 
and other health care team members.
Treatment options for diabetes  
in the elderly
Dietary changes may only moderately help with glycemic 
control in the elderly. These patients may have defective 
dentition, loss of taste/poor appetite, or an unwillingness 
to change a lifetime of eating habits.9 Elderly patients 
should consult with a dietitian to create a well balanced 
diet that facilitates weight loss (if needed) and helps main-
tain glycemic control.14 Exercise should be consistent and 
based on what the patient can tolerate. Preferably, these 
patients should walk or swim for 30 minutes a day to 
maintain muscle conditioning.9 Foot and eye care should 
be discussed with the patient. Pharmacists should review 
nonpharmacologic therapy, including lifestyle modifi-
cations, to determine if any changes could be made to 
improve effectiveness of recommended nonpharmacologic 
interventions. In addition, the pharmacist could discuss 
daily foot care, and could conduct a basic foot exam to 
assess pedal pulses, abnormalities in anatomy, and changes 
in sensation.
Pharmacologic treatment options are briefly presented 
in Table 1.1,4,9,14–19 To assess the effectiveness and safety 
of antihyperglycemic medications, the pharmacist should 
Table 1 Summary points for drugs used to treat diabetes in the elderly
Drug class/name Possible drug or disease  
interactions
Adverse events that  
may limit use
Important notes
Alpha-glucosidase  
inhibitors9
erratic oral intake; must 
take with main meals to be 
effective
Gastrointestinal effects Adjust dose with renal or liver dysfunction
Meglitinides1 Frequent daily dosing Hypoglycemia, weight gain Rapid onset
incretin therapies  
DPP-4 inhibitors15
Concomitant use with 
insulin secretagogues 
increases risk of 
hypoglycemia
Headache, infection, 
dermatologic effects16
•   effects are glucose dependent, so low risk  
for hypoglycemia
• weight neutral 
• Target PPG levels
incretin therapies  
GLP-1 agonists15
Concomitant use with 
insulin secretagogues 
increases risk of 
hypoglycemia
Gastrointestinal effects (less than 
alpha-glucosidase inhibitors),15 
pancreatitis, immune reactions 
(incidence less with liraglutide 
than exenatide)16
•   effects are glucose dependent, so low risk  
for hypoglycemia
• weight loss 
• Target PPG levels 
•   Decrease blood pressure; improve other  
CvD markers16
insulins17,18 erratic oral intake 
can increase risk of 
hypoglycemia; low vision 
and dexterity may limit use 
of vial and syringes, clinician 
inertia
Hypoglycemia •   Better glycemic control if difficulty adhering  
to oral medications, receiving multiple oral 
medications, or not achieving glycemic targets   
than with oral medications alone
•   early use may restore and improve beta-cell  
function
•   insulin pens increase adherence for patients  
with low vision and/or dexterity issues
Metformin1 impaired renal function Lactic acidosis (rare but serious), 
gastrointestinal effects
•   Measure serum creatinine and liver function  
periodically and with any increase in dose
• weight neutral versus placebo19
•   Avoid initiating in patients $80 years of age  
unless creatinine clearance is within normal  
limits
Pioglitazone14 Class iii and class iv 
congestive heart failure
Weight gain, fluid  
retention, peripheral edema, 
fractures among women19
Hypoglycemia rare
Sulfonylureas4 erratic oral intake can 
increase risk of hypoglycemia 
with long-acting agents
Hypoglycemia, weight gain Avoid long-acting sulfonylureas; short-acting  
(ie, glipizide) minimize risk of nocturnal  
hypoglycemia, and may also help avoid  
hypoglycemia in patients with erratic oral intake
Abbreviations: CvD, cardiovascular disease; DPP-4, dipeptidyl peptidase iv; GLP-1, glucagon-like peptide 1; NPH, neutral protamine Hagedorn; PPG, postprandial glucose.Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Pharmacist-provided patient care and associated outcomes in older patients with type 2 diabetes mellitus
Study Methods Results
Cranor et al24 •   Quasi-experimental, longitudinal, pre and post cohort  
trial design
•   12 community-based pharmacists trained in  
diabetes education
• Asheville Project 
•   Change in clinical and economic outcomes before  
and after up to 5 years of implementation of services
• n = 620 financial cohort, n = 565 clinical cohort 
• Baseline median age 48 years 
•   Median A1c decreased by 0.8% after first follow-up  
visit (P , 0.001)
•   LDL-C decreased by 2.5 mg/dL after the first follow-up  
visit (P = 0.13)
•   Total direct medical costs decreased by US$1662–$3356  
per patient per year depending on the follow-up year,  
despite increases in mean prescription costs
Fera et al5 •   Prospective, observational, pre- and post-cohort  
trial design
• Collaborative practice model 
• Community-based pharmacists 
• evidence-based guidelines 
• Clinical and economic outcomes 
• Diabetes Ten City Challenge 
•   Change in clinical and economic outcomes before  
and after 1 year of implementation of services
• N = 573 
• 42% were 60 years or older 
• Mean A1c decreased by 0.4% (P = 0.002) 
• Mean LDL-C decreased by 4 mg/dL (P , 0.001) 
• Mean SBP decreased by 3 mmHg (P , 0.001) 
•   Average total health care costs per patient per year  
decreased by US$1079 (7.2%)
•   Influenza vaccination rate increased by 33%
•   Foot examination rate increased by 40%
Jameson and Baty25 • Prospective, randomized, controlled trial 
• Pharmacist management versus usual medical care 
• Change in A1c after 1 year of care 
• Poorly controlled diabetes (A1c . 9%) 
• One pharmacist with advanced diabetes education training 
•   intervention consisted of targeted patient outreach  
program plus medication management, patient education,  
disease control by a pharmacist
•   Control group used targeted patient outreach programs  
and registries
• N = 103 (intervention group n = 52, control group n = 51) 
• Mean age 49 years 
•   Mean A1c decreased by 1.5% for the intervention group  
and 0.4% for the control group (P = 0.06)
•   A1c decreased by at least 1% for 67.3% versus 41.2%,  
respectively (P = 0.02)
•   Male and nonwhite patients had greater improvement  
in A1c than female or white patients
Abbreviations: A1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
carefully monitor glucose levels (including PPG), weight, 
renal function, and blood pressure. Elderly persons are more 
likely to have renal dysfunction than other adults. Therefore, 
medications such as metformin should be used with caution 
in these patients because of the risk of developing lactic aci-
dosis, a rare but potentially fatal adverse effect that is more 
common in those with renal dysfunction. Gastrointestinal 
adverse effects can be debilitating in the older person. For 
example, glucagon-like peptide 1 (GLP-1) agonists are 
associated with treatment-limiting nausea; however, these 
agents have a low risk of hypoglycemia. The pharmacist 
can discuss ways to reduce or manage drug-induced nau-
sea or recommend switching to a therapy with a low risk 
of this adverse effect. Clinician inertia, delaying insulin 
therapy because of fears of hypoglycemia, and perceived 
lack of benefit can also be addressed by a pharmacist by 
communicating patient-specific needs to other members of 
the health care team.
As an individual ages, beta-cell function declines. 
Studies suggest that early use of insulin in the elderly 
restores and improves beta-cell function and induces disease 
remission.18,20 Simple insulin regimens with premeasured 
doses and easier injection systems (eg, insulin pens with 
easy-to-set dosages) are preferred in the elderly patient.21 
Timing of insulin doses relative to meals and adjusting doses 
based on meal content and caloric intake minimize the risk of 
hypoglycemia. For some elderly people, two daily injections 
using premixed insulin analog preparations or a long-acting 
insulin analog for basal control may be preferred to multiple 
oral   medications. Fasting and post-prandial glucose levels 
should be monitored and assessed to determine if target 
levels have been obtained. If control is unsatisfactory, a 
dose of rapid-acting insulin analog for prandial glucose 
control during the main meal could be added to the basal 
regimen. For the healthy older person, a combination of 
rapid- and long-acting insulin analogs would provide tight 
glycemic control and allow dosing flexibility. Elderly people 
who are not frail are more likely to benefit from long-term 
tight glycemic control, which is associated with a reduced 
risk of diabetes-related microvascular complications and Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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amputations. In addition, long-acting insulin analogs do not 
have the pronounced peak observed with neutral protamine 
Hagedorn (NPH) insulin and are less likely to produce noc-
turnal hypoglycemia.22
Pharmacists are in a key position to improve diabetes 
control in this potentially high-risk population. In obser-
vational and controlled trials, medication management 
and diabetes education provided by the pharmacist has 
been reported to improve A1c, blood pressure, and lipid 
parameters.23 In addition, these services increase patient 
satisfaction and decrease health care costs. The DTCC is 
an example of how pharmacy practice around the country 
is evolving to include patient education, medication therapy 
management, basic physical assessment, routine patient 
and caregiver follow up, and constant collaboration with 
other health care providers.5 A brief list of recently pub-
lished primary literature evaluating clinical outcomes and 
pharmacist-provided diabetes care of the older patient is 
provided in Table 2.5,24,25
Older persons with diabetes are at greater risk of death 
from CVD than from intermittent hyperglycemia. Frail 
elderly people are more prone to develop complications from 
hypoglycemia, such as confusion and dementia. Continuity 
of care, communication with other members of the patient’s 
health care team, and a comprehensive medication review 
by the pharmacist, with subsequent recommendations to 
individualize therapy based on medical and cognitive sta-
tus, will minimize adverse effects and optimize treatment 
effectiveness.
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